Published in Arthritis Rheum on September 01, 2003
The benefits of early treatment in rheumatoid arthritis: confounding by indication, and the issue of timing. Arthritis Rheum (2003) 1.84
Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis (2010) 10.97
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis (2013) 10.92
Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis. N Engl J Med (2006) 3.80
Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial. Ann Intern Med (2012) 3.49
CD4(+)CD25(+) regulatory T cells in rheumatoid arthritis: differences in the presence, phenotype, and function between peripheral blood and synovial fluid. Arthritis Rheum (2004) 3.36
Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial. Ann Intern Med (2002) 3.10
Evidence for treating rheumatoid arthritis to target: results of a systematic literature search. Ann Rheum Dis (2010) 2.91
Proinflammatory mediator-induced reversal of CD4+,CD25+ regulatory T cell-mediated suppression in rheumatoid arthritis. Arthritis Rheum (2007) 2.81
Five-year followup of rheumatoid arthritis patients after early treatment with disease-modifying antirheumatic drugs versus treatment according to the pyramid approach in the first year. Arthritis Rheum (2003) 2.68
Modulation of monocyte/macrophage function by human CD4+CD25+ regulatory T cells. Hum Immunol (2005) 2.53
Is radiation synovectomy for arthritis of the knee more effective than intraarticular treatment with glucocorticoids? Results of an eighteen-month, randomized, double-blind, placebo-controlled, crossover trial. Arthritis Rheum (2005) 2.38
EULAR recommendations for the non-pharmacological core management of hip and knee osteoarthritis. Ann Rheum Dis (2013) 2.33
Antigen-specific T cell suppression by human CD4+CD25+ regulatory T cells. Eur J Immunol (2002) 2.18
Improved multiplex immunoassay performance in human plasma and synovial fluid following removal of interfering heterophilic antibodies. J Immunol Methods (2005) 2.09
Crosslinking by advanced glycation end products increases the stiffness of the collagen network in human articular cartilage: a possible mechanism through which age is a risk factor for osteoarthritis. Arthritis Rheum (2002) 1.85
Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial. Ann Rheum Dis (2007) 1.83
How psychological stress via hormones and nerve fibers may exacerbate rheumatoid arthritis. Arthritis Rheum (2005) 1.70
Effectiveness of behavioral graded activity in patients with osteoarthritis of the hip and/or knee: A randomized clinical trial. Arthritis Rheum (2006) 1.64
Psychometric evaluation of osteoarthritis questionnaires: a systematic review of the literature. Arthritis Rheum (2006) 1.60
Look beyond the disease activity score of 28 joints (DAS28): tender points influence the DAS28 in patients with rheumatoid arthritis. J Rheumatol (2011) 1.56
Stress-vulnerability factors as long-term predictors of disease activity in early rheumatoid arthritis. J Psychosom Res (2003) 1.55
Follow-up standards and treatment targets in rheumatoid arthritis: results of a questionnaire at the EULAR 2008. Ann Rheum Dis (2009) 1.48
Metabolic effects of high-dose prednisolone treatment in early rheumatoid arthritis: balance between diabetogenic effects and inflammation reduction. Arthritis Rheum (2012) 1.48
Current view of glucocorticoid co-therapy with DMARDs in rheumatoid arthritis. Nat Rev Rheumatol (2010) 1.48
Pain coping and social support as predictors of long-term functional disability and pain in early rheumatoid arthritis. Behav Res Ther (2003) 1.41
Accumulation of advanced glycation end products as a molecular mechanism for aging as a risk factor in osteoarthritis. Arthritis Rheum (2004) 1.39
Hypothesis - dietary glutamate will not affect pain in fibromyalgia. J Rheumatol (2004) 1.39
Determinants of discordance in patients' and physicians' rating of rheumatoid arthritis disease activity. Arthritis Care Res (Hoboken) (2012) 1.37
Performance of a multi-biomarker score measuring rheumatoid arthritis disease activity in the CAMERA tight control study. Ann Rheum Dis (2012) 1.28
Increased intraarticular interleukin-7 in rheumatoid arthritis patients stimulates cell contact-dependent activation of CD4(+) T cells and macrophages. Arthritis Rheum (2005) 1.27
"Beating osteoARThritis": development of a stepped care strategy to optimize utilization and timing of non-surgical treatment modalities for patients with hip or knee osteoarthritis. Clin Rheumatol (2011) 1.24
Rheumatology education in Europe: results of a survey of young rheumatologists. Clin Exp Rheumatol (2011) 1.23
Exposure of human cartilage tissue to low concentrations of blood for a short period of time leads to prolonged cartilage damage: an in vitro study. Arthritis Rheum (2007) 1.22
Misclassification of disease activity when assessing individual patients with early rheumatoid arthritis using disease activity indices that do not include joints of feet. Ann Rheum Dis (2011) 1.22
Blockade of the interleukin-7 receptor inhibits collagen-induced arthritis and is associated with reduction of T cell activity and proinflammatory mediators. Arthritis Rheum (2010) 1.17
Differential direct effects of cyclo-oxygenase-1/2 inhibition on proteoglycan turnover of human osteoarthritic cartilage: an in vitro study. Arthritis Res Ther (2006) 1.16
Persistence of interleukin 7 activity and levels on tumour necrosis factor alpha blockade in patients with rheumatoid arthritis. Ann Rheum Dis (2006) 1.11
A shift in the balance of inhibitory and activating Fcgamma receptors on monocytes toward the inhibitory Fcgamma receptor IIb is associated with prevention of monocyte activation in rheumatoid arthritis. Arthritis Rheum (2004) 1.10
Measurement of joint space width and erosion size. J Rheumatol (2005) 1.09
Interleukin 10 treatment of patients with rheumatoid arthritis enhances Fc gamma receptor expression on monocytes and responsiveness to immune complex stimulation. J Rheumatol (2003) 1.06
Elevated expression of interleukin-7 receptor in inflamed joints mediates interleukin-7-induced immune activation in rheumatoid arthritis. Arthritis Rheum (2009) 1.05
Neuroendocrine-immune interactions in synovitis. Nat Clin Pract Rheumatol (2007) 1.05
Followup radiographic data on patients with rheumatoid arthritis who participated in a two-year trial of prednisone therapy or placebo. Arthritis Rheum (2006) 1.04
From bone biology to clinical outcome: state of the art and future perspectives. Ann Rheum Dis (2010) 1.02
Clinical benefit of joint distraction in the treatment of severe osteoarthritis of the ankle: proof of concept in an open prospective study and in a randomized controlled study. Arthritis Rheum (2002) 1.02
Health and physiological effects of an emotional disclosure intervention adapted for application at home: a randomized clinical trial in rheumatoid arthritis. Psychother Psychosom (2009) 1.01
Effects of anger and anger regulation styles on pain in daily life of women with fibromyalgia: a diary study. Eur J Pain (2009) 1.01
Are glucocorticoids DMARDs? Ann N Y Acad Sci (2006) 1.01
Evaluation and management of endocrine dysfunction in fibromyalgia. Rheum Dis Clin North Am (2002) 1.00
Tissue structure modification in knee osteoarthritis by use of joint distraction: an open 1-year pilot study. Ann Rheum Dis (2011) 1.00
Prevention of glucocorticoid induced osteoporosis with alendronate or alfacalcidol: relations of change in bone mineral density, bone markers, and calcium homeostasis. J Rheumatol (2007) 1.00
Differential cytokine profiles in juvenile idiopathic arthritis subtypes revealed by cluster analysis. Rheumatology (Oxford) (2009) 1.00
Celecoxib: considerations regarding its potential disease-modifying properties in osteoarthritis. Arthritis Res Ther (2011) 0.96
Emotions and emotional approach and avoidance strategies in fibromyalgia. J Psychosom Res (2008) 0.95
Initiation of degenerative joint damage by experimental bleeding combined with loading of the joint: a possible mechanism of hemophilic arthropathy. Arthritis Rheum (2004) 0.95
Glucocorticoid chronotherapy in rheumatoid arthritis. Lancet (2008) 0.94
Glucocorticoids. Best Pract Res Clin Rheumatol (2011) 0.94
Longterm predictors of anxiety and depressed mood in early rheumatoid arthritis: a 3 and 5 year followup. J Rheumatol (2002) 0.93
Quantitative radiographic features of early knee osteoarthritis: development over 5 years and relationship with symptoms in the CHECK cohort. J Rheumatol (2012) 0.92
Health care use of patients with osteoarthritis of the hip or knee after implementation of a stepped-care strategy: an observational study. Arthritis Care Res (Hoboken) (2014) 0.92
Revisiting the toxicity of low-dose glucocorticoids: risks and fears. Ann N Y Acad Sci (2006) 0.92
Multinational evidence-based recommendations for pain management by pharmacotherapy in inflammatory arthritis: integrating systematic literature research and expert opinion of a broad panel of rheumatologists in the 3e Initiative. Rheumatology (Oxford) (2012) 0.92
Influence of various recruitment strategies on the study population and outcome of a randomized controlled trial involving patients with osteoarthritis of the hip or knee. Arthritis Rheum (2005) 0.92
Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity. Cochrane Database Syst Rev (2014) 0.91
The role of ectopic germinal centers in the immunopathology of primary Sjögren's syndrome: a systematic review. Semin Arthritis Rheum (2012) 0.91
The combination of the biomarkers urinary C-terminal telopeptide of type II collagen, serum cartilage oligomeric matrix protein, and serum chondroitin sulfate 846 reflects cartilage damage in hemophilic arthropathy. Arthritis Rheum (2009) 0.91
Role of neuroendocrine and neuroimmune mechanisms in chronic inflammatory rheumatic diseases--the 10-year update. Semin Arthritis Rheum (2013) 0.91
The cost effectiveness of behavioural graded activity in patients with osteoarthritis of hip and/or knee. Ann Rheum Dis (2006) 0.90
Suppression of inflammation and joint destruction in rheumatoid arthritis may require a concerted action of Th2 cytokines. Curr Opin Investig Drugs (2002) 0.89
Social support and invalidation by others contribute uniquely to the understanding of physical and mental health of patients with rheumatic diseases. J Health Psychol (2012) 0.89
Psychological and somatic predictors of perceived and measured ocular dryness of patients with primary Sjögren's syndrome. J Rheumatol (2005) 0.89
Role of ultrasonography in diagnosing early rheumatoid arthritis and remission of rheumatoid arthritis--a systematic review of the literature. Arthritis Res Ther (2013) 0.88
Interleukin-7-aggravated joint inflammation and tissue destruction in collagen-induced arthritis is associated with T-cell and B-cell activation. Arthritis Res Ther (2012) 0.88
Selective elimination of synovial inflammatory macrophages in rheumatoid arthritis by an Fcgamma receptor I-directed immunotoxin. Arthritis Rheum (2003) 0.88
Agreement of general practitioners with the guideline-based stepped-care strategy for patients with osteoarthritis of the hip or knee: a cross-sectional study. BMC Fam Pract (2013) 0.88
Elevation of cartilage AGEs does not accelerate initiation of canine experimental osteoarthritis upon mild surgical damage. J Orthop Res (2012) 0.87
IL-7 drives Th1 and Th17 cytokine production in patients with primary SS despite an increase in CD4 T cells lacking the IL-7Rα. Rheumatology (Oxford) (2012) 0.87
Pharmacology of glucocorticoids in rheumatoid arthritis. Curr Opin Pharmacol (2010) 0.87
Do rheumatoid arthritis patients have equal access to treatment with new medicines?: tumour necrosis factor-alpha inhibitors use in four European countries. Health Policy (2011) 0.87
Low-dose glucocorticoid therapy in rheumatoid arthritis: an obligatory therapy. Ann N Y Acad Sci (2010) 0.86
The match-mismatch model of emotion processing styles and emotion regulation strategies in fibromyalgia. J Psychosom Res (2011) 0.86
Glucocorticoids in rheumatoid arthritis: effects on erosions and bone. Ann N Y Acad Sci (2002) 0.86
Gender differences in emotion regulation and relationships with perceived health in patients with rheumatoid arthritis. Women Health (2005) 0.86
The association of fatigue, comorbidity burden, disease activity, disability and gross domestic product in patients with rheumatoid arthritis. Results from 34 countries participating in the Quest-RA program. Clin Exp Rheumatol (2014) 0.86
Increase of body mass index in a tight controlled methotrexate-based strategy with prednisone in early rheumatoid arthritis: side effect of the prednisone or better control of disease activity? Arthritis Care Res (Hoboken) (2013) 0.85